Brekke O H, Løset G Å
Affitech New Technologies, Gaustadalleen 21, N-0349 Oslo, Norway.
Curr Opin Pharmacol. 2003 Oct;3(5):544-50. doi: 10.1016/j.coph.2003.05.002.
The development of therapeutic antibodies took a sharp turn with the introduction of phage display technology over a decade ago. Antibodies are used in a whole range of disease fields, such as autoimmunity, cancer, inflammation and infectious diseases. Now, the first antibody derived from phage display technology has been approved in the US by the Food and Drug Administration. The antibody industry is continuously developing new and robust discovery platforms and novel antibody formats, which points to the versatility of antibodies as therapeutic and diagnostic agents.
十多年前噬菌体展示技术的引入使治疗性抗体的发展发生了重大转变。抗体被应用于一系列疾病领域，如自身免疫、癌症、炎症和传染病。如今，首个源自噬菌体展示技术的抗体已在美国获得食品药品监督管理局的批准。抗体行业不断开发新的、强大的发现平台和新型抗体形式，这表明抗体作为治疗和诊断试剂具有多功能性。
